NEULAND LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of NEULAND LABORATORIES have increased by 36.98% YoY .
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 39.94 % YoY. |
||
NEULAND LABORATORIES Last 5 Annual Financial Results
[BOM: 524558|NSE : NEULANDLAB]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,023 Cr | ₹1,477 Cr | ₹1,559 Cr | ₹1,191 Cr | ₹951 Cr |
| Expenses | ₹1,448 Cr | ₹1,154 Cr | ₹1,096 Cr | ₹919 Cr | ₹808 Cr |
| Operating Profit (Excl OI) | ₹574 Cr | ₹323 Cr | ₹463 Cr | ₹272 Cr | ₹143 Cr |
| Other Income | ₹30 Cr | ₹21 Cr | ₹13 Cr | ₹9.75 Cr | ₹2.08 Cr |
| Interest | ₹24 Cr | ₹8.30 Cr | ₹14 Cr | ₹13 Cr | ₹13 Cr |
| Depreciation | ₹92 Cr | ₹66 Cr | ₹60 Cr | ₹53 Cr | ₹49 Cr |
| Profit Before Tax | ₹489 Cr | ₹346 Cr | ₹401 Cr | ₹216 Cr | ₹82 Cr |
| Profit After Tax | ₹364 Cr | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr |
| Consolidated Net Profit | ₹364 Cr | ₹260 Cr | ₹300 Cr | ₹164 Cr | ₹64 Cr |
| Earnings Per Share (Rs) | ₹283.71 | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 |
| PAT Margin (%) | 17.99 | 17.61 | 19.25 | 13.73 | 6.71 |
| ROE(%) | 21.43 | 18.54 | 26.38 | 17.84 | 7.85 |
| ROCE(%) | 27.50 | 23.45 | 33.51 | 20.94 | 9.44 |
| Total Debt/Equity(x) | 0.10 | 0.09 | 0.06 | 0.12 | 0.28 |
Key Financials |
||
| Market Cap | : | ₹ 26,773.2 Cr |
| Revenue (TTM) | : | ₹ 2,307.2 Cr |
| Net Profit(TTM) | : | ₹ 452.5 Cr |
| EPS (TTM) | : | ₹ 353.6 |
| P/E (TTM) | : | 59.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NEULAND LABORATORIES | 6.2% | 2.8% | 13.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 6.7% | 12% |
| DIVIS LABORATORIES | 11.1% | 23.5% | 70% |
| TORRENT PHARMACEUTICALS | 1% | 1.8% | 34.3% |
| CIPLA | 0.1% | 6% | -5.8% |
| DR REDDYS LABORATORIES | 1.1% | 11.8% | 14.2% |
| MANKIND PHARMA | 3.7% | 11.2% | 17.4% |
| LUPIN | 1.2% | 2.8% | 2.5% |
| ZYDUS LIFESCIENCES | -0.5% | 4.5% | 29.6% |
NEULAND LABORATORIES Revenues
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 36.98 % |
| 5 Yr CAGR | 20.77 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,023 Cr | 36.98 | |
| Mar2025 | ₹1,477 Cr | -5.24 | |
| Mar2024 | ₹1,559 Cr | 30.84 | |
| Mar2023 | ₹1,191 Cr | 25.25 | |
| Mar2022 | ₹951 Cr | - | |
NEULAND LABORATORIES Operating Profit
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 77.72 % |
| 5 Yr CAGR | 41.67 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹574 Cr | 77.72 | |
| Mar2025 | ₹323 Cr | -30.12 | |
| Mar2024 | ₹463 Cr | 70.17 | |
| Mar2023 | ₹272 Cr | 90.61 | |
| Mar2022 | ₹143 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 29.74 % |
| 5 Yr CAGR | 17.30 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 28.4% | 29.74 | |
| Mar2025 | 21.89% | -26.25 | |
| Mar2024 | 29.68% | 30.06 | |
| Mar2023 | 22.82% | 52.13 | |
| Mar2022 | 15% | - | |
NEULAND LABORATORIES Profit After Tax
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 39.94 % |
| 5 Yr CAGR | 54.54 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹364 Cr | 39.94 | |
| Mar2025 | ₹260 Cr | -13.32 | |
| Mar2024 | ₹300 Cr | 83.51 | |
| Mar2023 | ₹164 Cr | 156.21 | |
| Mar2022 | ₹64 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 2.16 % |
| 5 Yr CAGR | 27.96 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 17.99 % | 2.16 | |
| Mar2025 | 17.61 % | -8.52 | |
| Mar2024 | 19.25 % | 40.20 | |
| Mar2023 | 13.73 % | 104.62 | |
| Mar2022 | 6.71 % | - | |
NEULAND LABORATORIES Earnings Per Share (EPS)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 39.94 % |
| 5 Yr CAGR | 54.54 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹284 | 39.94 | |
| Mar2025 | ₹203 | -13.32 | |
| Mar2024 | ₹234 | 83.52 | |
| Mar2023 | ₹127 | 156.23 | |
| Mar2022 | ₹50 | - | |
NEULAND LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 17.27 % |
| 5 Yr CAGR | 30.64 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 27.5% | 17.27 | |
| Mar2025 | 23.45% | -30.02 | |
| Mar2024 | 33.51% | 60.03 | |
| Mar2023 | 20.94% | 121.82 | |
| Mar2022 | 9.44% | - | |
NEULAND LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹20,916.6 |
| Current MarketCap | : | ₹ 26,773.2 Cr |
| Updated EOD on | : | Nov 12,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 6.2% |
2.8% |
13.4% |
| SENSEX | 3.3% |
13.9% |
-1.7% |
NEULAND LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 3.1% | 8.5% | 19.1% |
| BSE 500 MOMENTUM 50 | 2.8% | 4.4% | 6% |
| BSE SMALLCAP SELECT INDEX | 2.7% | 0.9% | 12.1% |
| BSE 500 | 2.7% | 9.4% | 1.2% |
| BSE 1000 | 2.7% | 8.7% | 1.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 50 | 3.3% | 3.4% | 14.5% |
| NIFTY500 HEALTHCARE INDEX | 3.1% | 9.3% | 19% |
| NIFTY SMALLCAP 100 | 3% | 1.5% | 8.9% |
| NIFTY TOTAL MARKET | 2.8% | 9% | 1.9% |
| NIFTY 500 | 2.8% | 9.4% | 1.5% |
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES Financials
How the annual revenues of NEULAND LABORATORIES have changed ?
The Revenues of NEULAND LABORATORIES have increased by 36.98% YoY .
How the Earnings per Share (EPS) of NEULAND LABORATORIES have changed?
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 39.94 % YoY .
Check out Intrinsic Value of Peers of NEULAND LABORATORIES
Compare Stock Analytics of Peers of NEULAND LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
